Valeant Pharmaceuticals Buys Russia’s Natur Produkt


Saint Petersburg

Montréal, Québec-based Valeant Pharmaceuticals International Inc., which develops, manufactures and markets pharmaceutical products, primarily in the areas of dermatology, neurology and branded generics, closed its acquisition of Natur Produkt International JSC, a specialty pharmaceutical company located in Saint Petersburg, Russia. The purchase price was approximately C$163 million. Natur Produkt has in past received investment from Russian private equity firms Renova Capital and Quadriga Capital Russia.

PRESS RELEASE

Valeant Completes Acquisition Of Natur Produkt In Russia

MONTREAL, Feb. 1, 2013 /PRNewswire/ — Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) today announced the completion of its acquisition of Natur Produkt International, JSC, a specialty pharmaceutical company in Russia, for approximately $163 million, plus adjustments for net debt and working capital. Natur Produkt has a significant presence in the over-the-counter (OTC) segment in several categories marketed under the umbrella brand, Natur Produkt. Key brands include AntiGrippin, a leading cough and cold remedy, Anti Angin, Sage and Eucaplyptus MA brand names, leading sore throat remedies.

About Valeant Pharmaceuticals International, Inc.
Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) is a multinational specialty pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of dermatology, neurology and branded generics. More information about Valeant Pharmaceuticals International, Inc. can be found at www.valeant.com.

Contact Information:
Laurie W. Little
949-461-6002
[email protected]

SOURCE Valeant Pharmaceuticals International, Inc.

 Photo courtesy of Shutterstock.

Do you want exclusive news and analysis about private equity deals, fundraising, top-quartile managers and more? Get your FREE trial to Buyouts! Or subscribe now!